Kezar在第四季度业绩和领先资产中期数据后下跌

Kezar Life Sciences (NASDAQ:KZR) traded lower on Tuesday after the company announced its Q4 2024 financial results alongside data from a mid-stage trial for its lead asset zetomipzomib in patients with autoimmune hepatitis, an inflammatory liver disorder.

Announcing Q4 financials, the San Francisco, California-based biotech posted a $7M year-over-year revenue drop and ~34% YoY decline in cash, cash equivalents, and marketable securities, which reached $132.2M as of Dec. 31.

As for data from its PORTOLA Phase 2a clinical trial, which was not powered for efficacy, Kezar (NASDAQ:KZR) said per its topline data, zetomipzomib led to complete biochemical responses (CR) in 50.0% (8 of 16) of patients within 24 weeks without considering a protocol-suggested steroid taper.

In comparison, nearly 38% of those on placebo (3 of 8) witnessed CR, while about 19% (3 of 16) of patients on zetomipzomib achieved both a CR and complete steroid withdrawal compared to none in the placebo arm (0 of 8).

As for safety, all patients indicated treatment-emergent adverse events, while two in the zetomipzomib arm and one in the placebo arm experienced treatment-emergent serious adverse events. All SAEs were not related to the experimental therapy, the company said, adding that there were three trial discontinuations in the zetomipzomib arm following Grade 1/2 adverse events.